Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
1. A method of treating a disease in a patient, wherein said disease is selected from cachexia, acute myelogenous leukemia, acute lymphoblastic leukemia, and chronic myelomonocytic leukemia, comprising administering to said patient a therapeutically effective amount of a compound which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein said treating refers to ameliorating or inhibiting the disease in the patient.
2. The method according to claim 1 , wherein said compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
3. The method according to claim 2 , wherein said disease is acute myelogenous leukemia.
4. The method according to claim 2 , wherein said disease is chronic myelomonocytic leukemia.
5. The method according to claim 2 , wherein said disease is cachexia.
6. The method according to claim 5 , wherein said cachexia results from or is associated with cancer.
7. The method according to claim 2 , wherein said disease is acute lymphoblastic leukemia.